NCT02227550 - Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy | Biotech Hunter

Enrollment

676

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2017

Study Completion Date

September 30, 2017

Conditions

Atrial Fibrillation

Interventions

DRUG

Vitamin K antagonist

any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin

DRUG

Apixaban

factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine \>= 1.5 mg/dl (133mM), \<= 60 kg body weight or age \>= 80 years.

Trial Locations (13)

Unknown

Montefiore Medical Center, New York

Hospital of the University of Pennsyvlania, Philadelphia

Vanderbilt University Medical Center, Nashville

Texas Cardiac Arrhythmia Research, Austin

Sentara Cariovascular Research Insititute, Norfolk

4 Sites, Different

5 Sites, Different

13 Sites, Different

4 Sites, Different

6 Sites, Different

3 Sites, Different

4 Sites, Different